Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab
Rita De Sanctis(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Giovanna Masci(Humanitas University), Monica Zuradelli(Humanitas University), Federica D’Antonio(Humanitas University), Elisa Agostinetto(Université Libre de Bruxelles), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Arianna Marinello(Humanitas University), Agnese Losurdo(Humanitas University), D. Guiducci(Humanitas University), Rosalba Torrisi(IRCCS Humanitas Research Hospital)
Cited by 10
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532